43071-45-0

Usage

Uses

Used in Pharmaceutical Industry:
3-METHYL-2-PHENYL-QUINOLINE-4-CARBOXYLIC ACID is used as a potential drug candidate or a precursor for drug synthesis due to its potential biological activity. Its unique structure may contribute to the development of new therapeutic agents with specific pharmacological properties.
Used in Organic Synthesis:
In the field of organic synthesis, 3-METHYL-2-PHENYL-QUINOLINE-4-CARBOXYLIC ACID serves as a valuable intermediate or building block for the synthesis of more complex organic molecules. Its presence of functional groups, such as the carboxylic acid, allows for further chemical reactions and modifications, expanding its utility in creating novel compounds.
Used in Materials Science:
3-METHYL-2-PHENYL-QUINOLINE-4-CARBOXYLIC ACID is used in materials science for its unique structural and property contributions. Its incorporation into various materials may lead to the development of new materials with enhanced properties, such as improved stability, reactivity, or selectivity in specific applications.

InChI:InChI=1/C17H13NO2/c1-11-15(17(19)20)13-9-5-6-10-14(13)18-16(11)12-7-3-2-4-8-12/h2-10H,1H3,(H,19,20)/p-1

Upstream product

• 91-56-5 indole-2,3-dione 
• 93-55-0 1-phenyl-propan-1-one 
• 2051-95-8 succinylbenzene 
• 43071-31-4 3-(carboxymethyl)-2-phenylquinoline-4-carboxylic acid 

Downstream Products

• 174636-71-6 3-methyl-2-phenylquinoline-4-carbonyl chloride 
• 74960-43-3 3-methyl-2-phenyl-quinoline-4-carboxylic acid methyl ester 
• 174635-69-9 (-)-(S)-N-(α-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide 
• 224633-15-2 3-(bromomethyl)-2-phenylquinoline-4-carboxylic cid 
• 65417-26-7 methyl 4-methyl-2-phenyl-3,1-benzoxazepine-5-carboxylate 
• 65417-28-9 methyl 3-acetyl-2-phenyl-3H-indole-3-carboxylate 
• 36779-17-6 methyl 2-phenyl-1H-indole-3-carboxylate 
• 65417-21-2 methyl 3-methyl-2-phenylquinoline-4-carboxylate 1-oxide 
• 74960-55-7 methyl 1-acetyl-2-phenylindole-3-carboxylate 
• 1336960-15-6 3-(1,4'-bipiperidin-1'-ylmethyl)-2-phenyl-N-(1-phenylcyclopropyl)-4-quinolinecarboxamide 
• 5471-16-9 3-methyl-2-phenylquinoline-4-carboxylic acid ethyl ester 
• 345235-03-2 {1-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-phenyl-quinolin-3-ylmethyl]-piperidin-4-yl}-carbamic Acid 9H-fluoren-9-ylmethyl Ester 
• 270574-13-5 3-(4-Fmoc-piperazin-1-ylmethyl)-2-phenyl-quinoline-4-carboxylic Acid ((S)-1-cyclohexyl-ethyl)-amide 
• 270574-12-4 4-[2-phenyl-4-(1-phenyl-propylcarbamoyl)-quinolin-3-ylmethyl]-piperazine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 

Relevant academic research and scientific papers

Synthesis and Antimicrobial Activity of 1,3,4-Oxadiazole-2(3H)-thione and Azidomethanone Derivatives Based on Quinoline-4-carbohydrazide Derivatives

A new series compounds of quinoline derivatives were synthesized by reaction of 3-(carboxymethyl)-2-arylquinoline-4-carboxylic acids 1a, 1b, 1c with different nucleophiles. The structures of the new compounds were elucidated on the basis of FTIR,1/s

TRPV4 ANTAGONISTS

The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Quinoline derivatives as neurokinin receptor antagonists

The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R1, R2, R3, R4, R5, X, Y and Z are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.

QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS

The present invention relates to substituted quinoline-4-carboxylic acid hydrazides defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors.

Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase

A series of 2-phenyl quinoline-4-carboxylic acid derivatives related to brequinar, an inhibitor of human dihydroorotate dehydrogenase (DHODH), has been prepared and evaluated as inhibitors of DHODH from the malaria parasite Plasmodium falciparum. Brequinar was essentially inactive against PfDHODH (IC50 880 μM) whereas several members of the series inhibited PfDHODH. Unexpectedly, replacement of the carboxylic acid required for brequinar to inhibit hDHODH was not essential in the diisopropylamides that inhibited PfDHODH.

QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS

The invention relates to novel quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments particularly in treating disorders of the central nervous system (CNS).

N-type calcium channel antagonists for the treatment of pain

Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R1, R2, R3, R4 and R5 are any of a number of groups as defined in the specification, A and D are as

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3- hydroxy-2-phenylquinoline-4-carboxamide (SB 223412)

Optimization of the previously reported 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonist 14, with regard to potential metabolic instability of the ester moiety and affinity and selectivity for the human neurokinin-3 (hNK-3) receptor, is described. The ester functionality could be successfully replaced by the ketone (31) or by lower alkyl groups (Et, 21, or n-Pr, 24). Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. All of the chemical groups introduced at this position, with the exception of halogens, increased the hNK-3 binding affinity, and compounds 53 (3-OH, SB 223412, hNK- 3-CHO binding K(i) = 1.4 nM) and 55 (3-NH2, hNK-3-CHO binding K(i) = 1.2 nM) were the most potent compounds of this series. Selectivity studies versus the other neurokinin receptors (hNK-2-CHO and hNK-1-CHO) revealed that 53 is about 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 μM. In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca2+ mobilization in CHO cells stably expressing the hNK-3 receptor), while in vive this compound showed oral and intravenous activity in NK-3 receptor-driven models (senktide-induced behavioral responses in mice and senktide-induced miosis in rabbits). Overall, the biological data indicate that (S)-N-(1-phenylpropyl)-3-hydroxy- 2-phenylquinoline-4-carboxamide (53, SB 223412) may serve as a pharmacological tool in animal models of disease to assess the functional and pathophysiological role of the NK-3 receptor and to establish therapeutic indications for non-peptide NK-3 receptor antagonists.